{
    "clinical_study": {
        "@rank": "88845", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "maltodextrin powder to be taken daily"
            }, 
            {
                "arm_group_label": "Probiotic", 
                "arm_group_type": "Active Comparator", 
                "description": "Probiotic blended in maltodextrin powder to be taken daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the current study is to evaluate the efficacy of administering a probiotic in\n      adult human subjects suffering from allergic rhinitis during seasonal grass pollen exposure."
        }, 
        "brief_title": "Effect of a Probiotic on Seasonal Allergic Rhinitis Symptoms", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Adult subjects with documented seasonal allergic rhinitis (SAR) to grass pollen will be\n      assigned to placebo or probiotic groups and take either placebo or probiotic dietary\n      intervention for 8 weeks during the grass pollen allergy season. Total nasal symptom score\n      (TNSS) will be compared over 8 weeks between the two treatment groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults aged 18 to 65 years of age at the time of enrolment.\n\n          -  Established seasonal allergic rhinitis (clinical history of rhinorrhea, congestion,\n             sneezing, pruritis >2 years)\n\n          -  Positive Skin Prick Test (SPT)to Grass Pollen (GP).\n\n          -  Presence of specific IgE to Grass Pollen (GP)\n\n          -  Have a Body Mass Index in the range 19-32 kg/m2\n\n          -  Have signed the consent form\n\n          -  Have been instructed during screening and agreed to not take any probiotic containing\n             products outside the study for the study period\n\n        Exclusion Criteria:\n\n          -  Subjects currently under treatment with antibiotics or undergoing allergen\n             immunotherapy at the time of enrolment\n\n          -  Pregnancy\n\n          -  Vasomotor rhinitis, nasal cavity disorders (nasal polyps), ear infections otitis\n             media).\n\n          -  Other chronic diseases (e.g. gastrointestinal, cardiovascular, infections)\n\n          -  Subjects diagnosed with asthma\n\n          -  Subjects currently participating in another interventional clinical trial or having\n             participated in another clinical trial in the last 2 months\n\n          -  Subjects on chronic use of systemic corticosteroids prior to randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "131", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653652", 
            "org_study_id": "11.31. NRC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotic", 
                "intervention_name": "Probiotic", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Maltodextrin", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "grass pollen", 
            "allergic rhinitis", 
            "TNSS", 
            "miniRQLQ"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Charit\u00e9 Research Organisation GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Mitigation of Seasonal Allergic Rhinitis Symptoms in Adults by Probiotic Intervention", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Total nasal symptom score (TNSS) measuring nasal congestion, runny nose, nasal itching and sneezing on a scale of 0-12 will be compared over 8 weeks between the two treatment groups.", 
            "measure": "Total nasal symptom score (TNSS)", 
            "safety_issue": "No", 
            "time_frame": "every day over 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total ocular symptom score (TOSS)", 
                "safety_issue": "No", 
                "time_frame": "every day over 8 weeks"
            }, 
            {
                "description": "Validated rhinoconjunctivitis quality of life questionnaire (mini RQLQ) measured weekly", 
                "measure": "miniRQLQ", 
                "safety_issue": "No", 
                "time_frame": "every week for 8 weeks"
            }, 
            {
                "measure": "Individual nasal and ocular symptoms scores", 
                "safety_issue": "No", 
                "time_frame": "every day over 8 weeks"
            }, 
            {
                "measure": "Well being index", 
                "safety_issue": "No", 
                "time_frame": "every week over 8 weeks"
            }, 
            {
                "measure": "Medication Score", 
                "safety_issue": "No", 
                "time_frame": "every week over 8 weeks"
            }, 
            {
                "measure": "Specific IgE", 
                "safety_issue": "No", 
                "time_frame": "Baseline and end of study"
            }
        ], 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}